[Treatment of multiple myeloma with a new cytostatic agent: gamma-l-methyl-5-bis-(beta-chlorethyl)-amino-benzimidazolyl-(2)-butyric acid hydrochloride].
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001796:Blood Protein Disorders / Q000188:drug therapy; D002087:Butyrates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007122:Immunoelectrophoresis; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*
D000970:Antineoplastic Agents; D002087:Butyrates; D007093:Imidazoles
Behandlung des multiplen myeloms mit einem neuen Zytostatikum: gamma-L-Methyl-5-bis(beta-chloräthyl)-amino-benzimidazolyl-(2)-buttersäure-hydrochlorid.